factually
Index/Topics/Garadacimab vs GaraHerb Safety and Efficacy

Garadacimab vs GaraHerb Safety and Efficacy

Comparing the safety and efficacy of garadacimab (marketed as ANDEMBRY) and GaraHerb, with garadacimab having substantial peer-reviewed clinical data and GaraHerb lacking independent clinical trials.

Fact-Checks

1 result
Jan 19, 2026

What clinical trials or peer‑reviewed studies exist on GaraHerb's ingredients and long‑term safety?

The reporting provided shows two different threads often conflated by name: robust, peer‑reviewed clinical trial programs exist for the monoclonal antibody garadacimab (marketed as ANDEMBRY) including...